PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026European Journal of Hospital Pharmacy0 citationsOpen Access

Evaluation of a pharmacist-led medication review and optimisation service in the management of cardiometabolic disease

View Full Paper
PCPauline ColemanBKBarry KeenanMMMonica Monaghan

Key Result

The pharmacist-led medication review service was feasible and acceptable to patients in promoting guideline-directed SGLT2i prescribing.

Key Points

  • This evaluation aims to assess the feasibility and patient acceptability of a pharmacist-led medication review service for cardiometabolic disease management.
  • Pharmacist-led intervention to optimize medication
  • Assessment of patient acceptability and feasibility
  • Exploration of SGLT2i prescribing guidelines
  • Pharmacist-led service demonstrated feasibility in delivery
  • Patients found the service acceptable
  • Supported operationalisation of guideline-directed SGLT2i prescribing

Structured PICO

Does a pharmacist-led medication review and optimisation service improve guideline-directed SGLT2i prescribing in patients with cardiometabolic disease?

P
Population
Patients with cardiometabolic disease
I
Intervention
Pharmacist-led medication review and optimisation service
O
Outcome
Feasibility, acceptability, and operationalisation of guideline-directed SGLT2i prescribing

A pharmacist-led medication review service is feasible and supports guideline-directed SGLT2i prescribing in cardiometabolic disease.

Limitations

  • Lack of longitudinal clinical and economic outcomes

Abstract

The pharmacist-led service was feasible to deliver, acceptable to patients and supported the operationalisation of guideline-directed SGLT2i prescribing. Further longitudinal studies are needed to determine clinical and economic outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Coleman et al. (2026) studied this question. The pharmacist-led medication review service was feasible and acceptable to patients in promoting guideline-directed SGLT2i prescribing.

synapsesocial.com/papers/69b4fc7fb39f7826a300d704https://doi.org/10.1136/ejhpharm-2025-004897
Ask AI
Helpful
Bookmark
Share
View Full Paper